Dysgraphia adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 6,518 adverse event reports that record the MedDRA preferred term Dysgraphia. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 248 reports in the 12 months to June 2026 and 281 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,282 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 248 (under 0.1%) record this term. Reports for female patients were 62% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 116 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Dysgraphia name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	25
Advair Diskus	Corticosteroid	13
Alemtuzumab	CD52-directed cytolytic antibody	44
Ampyra	Potassium channel blocker	260
Aripiprazole	Atypical antipsychotic	13
Aspirin	Nonsteroidal anti-inflammatory drug	10
Aubagio	Pyrimidine synthesis inhibitor	91
Avastin	Vascular endothelial growth factor inhibitor	18
Avonex	Interferon beta	357
Axicabtagene ciloleucel	CD19-directed chimeric antigen receptor	13
Blincyto		18
Bupropion hydrochloride	Aminoketone	20
Carbidopa levodopa	Aromatic amino acid	26
Carboplatin	Platinum-based drug	13
Celebrex	Nonsteroidal anti-inflammatory drug	30
Chantix	Partial cholinergic nicotinic agonist	23
Ciprofloxacin	Fluoroquinolone antibacterial	15
Clonazepam	Benzodiazepine	20
Copaxone		31
Cosentyx	Interleukin-17A antagonist	36
Crestor	HMG-CoA reductase inhibitor	22
Cyclophosphamide	Alkylating drug	20
Cyclosporine	Calcineurin inhibitor immunosuppressant	10
Cymbalta		26
Depakine		32
Depakine Chrono		46
Diazepam	Benzodiazepine	31
Dupixent	Interleukin-4 receptor alpha antagonist	11
Eliquis	Factor Xa inhibitor	17
Enbrel	Tumor necrosis factor blocker	85
Entresto	Angiotensin 2 receptor blocker	71
Escitalopram	Serotonin reuptake inhibitor	18
Ezetimibe	Dietary cholesterol absorption inhibitor	12
Fentanyl	Opioid agonist	11
Fludarabine	Nucleoside metabolic inhibitor	22
Forteo	Parathyroid hormone analog	33
Gabapentin	Anti-epileptic agent	23
Gilenya	Sphingosine 1-phosphate receptor modulator	244
Humalog	Insulin analog	22
Humira		110
Hydroxyzine	Antihistamine	13
Ibrance	Kinase inhibitor	36
Imbruvica	Kinase inhibitor	10
Inbrija	Aromatic amino acid	15
Insulin glargine	Insulin analog	13
Keppra		23
Kesimpta	CD20-directed cytolytic antibody	45
Kymriah	CD19-directed chimeric antigen receptor	17
Lamictal	Anti-epileptic agent	14
Lamotrigine	Anti-epileptic agent	27
Lantus	Insulin analog	14
Lantus Solostar	Insulin analog	17
Levetiracetam		26
Lipitor	HMG-CoA reductase inhibitor	21
Lyrica		262
Mayzent	Sphingosine 1-phosphate receptor modulator	27
Methotrexate	Folate analog metabolic inhibitor	11
Metoclopramide	Dopamine-2 receptor antagonist	13
Mirtazapine		21
Morphine sulfate	Opioid agonist	12
Naproxen	Nonsteroidal anti-inflammatory drug	10
Neurontin		29
Nexium	Proton pump inhibitor	33
Novothyrox		12
Nuplazid	Atypical antipsychotic	207
Ocrevus	CD20-directed cytolytic antibody	60
Omeprazole	Proton pump inhibitor	13
Oxaliplatin	Platinum-based drug	11
OxyContin	Opioid agonist	14
Pfizer-Biontech Covid-19 Vaccine		10
Plavix	P2Y12 platelet inhibitor	12
Plegridy	Interferon beta	21
Potassium chloride	Osmotic laxative	11
Prednisone	Corticosteroid	32
Pregabalin		40
Premarin	Estrogen	10
Quetiapine	Atypical antipsychotic	22
Ranolazine		10
Rebif	Interferon beta	31
Rinvoq	Janus kinase inhibitor	15
Risperdal	Atypical antipsychotic	11
Rituximab	CD20-directed cytolytic antibody	20
Rivaroxaban	Factor Xa inhibitor	11
Rivotril		10
Rytary	Aromatic amino acid	82
Sandostatin LAR Depot		16
Seroquel	Atypical antipsychotic	38
Sertraline	Serotonin reuptake inhibitor	31
Simvastatin	HMG-CoA reductase inhibitor	13
Skyrizi	Interleukin-23 antagonist	15
Symbicort	Corticosteroid	11
Synthroid	l-Thyroxine	11
Tasigna	Kinase inhibitor	15
Tecfidera		265
Tegretol	Mood stabilizer	10
Teriflunomide	Pyrimidine synthesis inhibitor	51
Tocilizumab	Interleukin-6 receptor antagonist	15
Topiramate		21
Trulicity	GLP-1 receptor agonist	13
Tysabri	Integrin receptor antagonist	530
Urbanyl		10
Valproate sodium	Anti-epileptic agent	126
Valproic acid	Anti-epileptic agent	29
Vesicare		11
Vincristine sulfate	Vinca alkaloid	20
Vioxx		10
Vumerity		24
Vyndamax		21
Xalatan	Prostaglandin analog	10
Xanax	Benzodiazepine	13
Xcopri		11
Xeljanz	Janus kinase inhibitor	190
Xyrem	Central nervous system depressant	16
Yescarta	CD19-directed chimeric antigen receptor	72
Zoloft	Serotonin reuptake inhibitor	12
Zyprexa	Atypical antipsychotic	20

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 32 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Dysgraphia name, in order of name
Class	Reports with this term
Alkylating drug	28
Angiotensin 2 receptor blocker	79
Anti-epileptic agent	243
Aromatic amino acid	135
Atypical antipsychotic	376
Benzodiazepine	105
CD19-directed chimeric antigen receptor	102
CD20-directed cytolytic antibody	127
CD52-directed cytolytic antibody	51
Corticosteroid	86
Factor Xa inhibitor	39
GLP-1 receptor agonist	26
HMG-CoA reductase inhibitor	66
Insulin analog	70
Integrin receptor antagonist	534
Interferon beta	413
Interleukin-17A antagonist	36
Janus kinase inhibitor	205
Kinase inhibitor	102
Nonsteroidal anti-inflammatory drug	69
Nucleoside metabolic inhibitor	34
Opioid agonist	64
P2Y12 platelet inhibitor	31
Parathyroid hormone analog	33
Potassium channel blocker	269
Proton pump inhibitor	59
Pyrimidine synthesis inhibitor	142
Serotonin and norepinephrine reuptake inhibitor	30
Serotonin reuptake inhibitor	81
Sphingosine 1-phosphate receptor modulator	273
Tumor necrosis factor blocker	96
Vascular endothelial growth factor inhibitor	31

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Dysgraphia, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Dysgraphia
Age	Reports	Share
Under 2	27	0.4%
2 to 11	73	1.1%
12 to 17	57	0.9%
18 to 44	530	8.1%
45 to 64	1,499	23%
65 to 74	736	11.3%
75 and over	590	9.1%
Age not given	3,006	46.1%

Sex of the patient in the reports that record Dysgraphia
Sex	Reports	Share
Female	4,043	62%
Male	2,114	32.4%
Unknown or not given	361	5.5%

Age and sex are as the report gives them. 77.8% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Dysgraphia: adverse event reports that record this term. https://reportedreactions.com/reaction/dysgraphia/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Dysgraphia mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page